270 filings
Page 4 of 14
8-K
fwecag1
11 Apr 22
Departure of Directors or Certain Officers
4:06pm
8-K
3ly32s
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
ejwq umfp
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
yj7gh2rkkc07gcl
14 Feb 22
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
12:00am
8-K
uws7ff
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
w56e16
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
08c6ryl2xz71q2j8ews
1 Jul 21
Other Events
6:11am
8-K
3jh qsvwnonushv6fj
14 Jun 21
Other Events
5:21pm
8-K
vx3h h6ro2abk1uat5r
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
iniqtefz9t6emren9xw
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
b7gszrb
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
0iy92en
18 May 21
Other Events
3:09pm
8-K
14h0o1tz
17 May 21
Submission of Matters to a Vote of Security Holders
6:08am
8-K
p2f gm4cni
11 May 21
Other Events
8:34am
8-K
4zrhex1t2tq0ff
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm